AbbVie Inc. (ABBV) FY2026 YTD Q2 P&L / Income Statement

AbbVie Inc. (ABBV) FY2026 YTD Q2 P&L / Income Statement

Income statement for 2026-01-01 through 2026-06-30. View: Key Product Portfolio by Product and Service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Net revenues

31,992,000,000 US dollars

Cost of products sold

8,509,000,000 US dollars

Gross profit (calculated)

23,483,000,000 US dollars

Operating expenses (calculated)

13,061,000,000 US dollars

Operating earnings

10,422,000,000 US dollars

Other income (expense), net (calculated)

negative 5,105,000,000 US dollars

Earnings before income tax expense

5,317,000,000 US dollars

Income tax expense

1,004,000,000 US dollars

Net earnings

4,313,000,000 US dollars

Aesthetics - Botox Cosmetic

1,396,000,000 US dollars

Aesthetics - Juvederm Collection

477,000,000 US dollars

Aesthetics - Other Aesthetics

595,000,000 US dollars

Immunology - Humira

1,444,000,000 US dollars

Immunology - Rinvoq

4,644,000,000 US dollars

Immunology - Skyrizi

9,988,000,000 US dollars

Neuroscience - Botox Therapeutic

2,051,000,000 US dollars

Neuroscience - Other Neuroscience

242,000,000 US dollars

Neuroscience - Qulipta

646,000,000 US dollars

Neuroscience - Ubrelvy

731,000,000 US dollars

Neuroscience - Vraylar

1,976,000,000 US dollars

Neuroscience - Vyalev

457,000,000 US dollars

Oncology - Elahere

409,000,000 US dollars

Oncology - Epkinly

186,000,000 US dollars

Oncology - Imbruvica

1,088,000,000 US dollars

Oncology - Venclexta

1,541,000,000 US dollars

Other Key Products - Linzess

578,000,000 US dollars

Other Key Products - Mavyret

646,000,000 US dollars

Undisclosed (calculated)

2,897,000,000 US dollars

Selling, general and administrative

7,210,000,000 US dollars

Research and development

4,816,000,000 US dollars

Acquired IPR&D and milestones

1,035,000,000 US dollars

Other operating income

0 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
• Of which attributable to AbbVie Inc.: $4.31 B; to noncontrolling interests: $5.00 M.